CoChat

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Singh, Juswinder, Evans, Erica, Hagel, Margit, Labinski, Matthew, Dubrovskiy, Alex, Nacht, Mariana, Petter, Russell C., Prasad, Aravind, Sheets, Michael, St Martin, Thia, Tjin Tham Sjin, Robert, Westlin, William, Zhu, Zhendong · 2012 · MedChemComm
Cited by 27

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Recently, the importance of targeted covalent inhibitors in addressing potency, selectivity and drug resistance has become of great interest, especially in the area of non-small cell lung cancer (NSCLC). Although several covalent EGFR TKIs that are advancing in NSCLC clinical development are active against mutations which are refractory to the reversible TKI drugs Tarceva and Iressa, limited chemical diversity has been explored; all of the irreversible and reversible clinical compounds share the same quinazoline scaffold. We describe the design of a novel pyrimidine-based irreversible inhibitor of EGFR (CNX17) which is active against both the WT EGFR as well as the resistance mutation L858R/T790M in biochemical assays. The inhibitor is also a potent inhibitor of EGFR signaling, including the L858R/T790M resistance mutation in cells (H1975 cell line, EC50 441 nM). Importantly, it also potently inhibits proliferation in both HCC827 (EGFRΔ746–750 EC50 < 5 nM) and H1975 (EC50 134 nM). This novel chemical scaffold may be an important addition to the armamentarium in overcoming drug resistance to current EGFR therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c2md20017a

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 27

Metadata

Authors
Singh, J., Evans, E., Hagel, M., Labinski, M., Dubrovskiy, A., Nacht, M., Petter, R. C., Prasad, A., Sheets, M., St Martin, T., Tjin Tham Sjin, R., Westlin, W., & Zhu, Z.
Venue
MedChemComm
Published
2012
Volume
3
Issue
7
Pages
780
ISSN
  • 2040-2503 (ISSN-L)
  • 2040-2511
OpenAlex
W2079945306
Cited by
27
References
4
FWCI
2.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance. https://app.cochat.ai/papers/10.1039/c2md20017a
The paper
Singh, J., Evans, E., Hagel, M., Labinski, M., Dubrovskiy, A., Nacht, M., Petter, R. C., Prasad, A., Sheets, M., St Martin, T., Tjin Tham Sjin, R., Westlin, W., & Zhu, Z. (2012). Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance. MedChemComm. https://doi.org/10.1039/c2md20017a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.